Effective January 1, 2015, the preferred short and intermediate acting insulin will be Novolin and Novolog for Commercial and Exchange Market formularies.

Humulin, Humalog, and Apidra will be non-preferred, and in most cases, will require a Prior Authorization (PA) or be excluded entirely from the Covered Person’s formulary.

To ensure a smooth transition for impacted Covered Persons, Participating Pharmacies are encouraged to assist their Covered Persons to get a new prescription from their Prescribing Provider.